
-
Iterum Therapeutics NasdaqCM:ITRM Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Location: 3 Dublin Landings, Dublin, D01 C4E0, Ireland | Website: https://www.iterumtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
58.59M
Cash
12.65M
Avg Qtr Burn
-4.187M
Short % of Float
3.28%
Insider Ownership
1.03%
Institutional Own.
6.41%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sulopenem (ORLYNVAH) Details Urinary tract infection | Approved Quarterly sales | |
Sulopenem Details Urinary tract infection | Failed Discontinued | |
Sulopenem Details Intra-abdominal infections | Failed Discontinued |